Study registration: *
Publication Lumley S, Clin Infect Dis, 2021
Dates: 2020-09-01 to 2021-02-28
Funding: Public/non profit (UK Government’s Department of Health and Social Care; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE); NIHR Biomedical Research Centre, Oxford; the Huo Family Foundation; Andrew Spokes. )
Conflict of interest: Yes (D. W. E. declares lecture fees from Gilead, outside the submitted work. R. J. C. is a founder, shareholder, and consultant to MIROBio, outside the submitted work. All other authors report no potential conflicts.)
Description of participants: Staff at 4 hospitals and associated facilities in Oxfordshire, UK.
Follow-up duration (months): 6.00
|Variant description :
Variant name: Alpha|
Evidence: Indirect evidence (prevalence of variant in the population: 56%)
In addition to the published report, the supplementary material were used in data extraction and risk of bias assessment. The prevalence reported for the Alpha variant was based on sequencing since December 1, 2020; however, results are for data from September 1, 2020.
The main concern is the potential for uncontrolled confounding. Although most confounders were adjusted for, the analysis did not control for symptoms at the time of potential vaccination, which is likely to be an important confounder.